Form 4: Avidity CMO Sells Shares for Tax Obligations

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, reported a non-discretionary sale of common stock totaling 4,895 shares to cover tax withholding obligations related to RSU vesting.

Summary

• Steven George Hughes, Chief Medical Officer of Avidity Biosciences, Inc. (RNA), reported the sale of 4,895 shares of common stock.
• The sales occurred on January 21, 2026, at a price of $72.45 per share.
• The transaction was a "sell-to-cover" to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) on January 20, 2026.
• This was a mandated, non-discretionary sale by the issuer's equity incentive plans and was executed under a Rule 10b5-1 plan.
• Following these transactions, Steven George Hughes beneficially owns 31,599 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary 'sell-to-cover' transaction for tax purposes, which is neutral in sentiment. It does not indicate any change in the company's operational or financial performance.

Positives

• The transaction is a routine, non-discretionary "sell-to-cover" to meet tax obligations, indicating no voluntary divestment by the officer.
• The sale was pre-planned under a Rule 10b5-1 plan, demonstrating adherence to insider trading regulations.

Negatives

• No specific negatives are identified as this is a routine, non-discretionary transaction for tax purposes.

Future Outlook

The filing details a pre-scheduled transaction for January 21, 2026, indicating a planned future event related to executive compensation and tax obligations.

Management Comments

• This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person.
• The Reporting Person has executed an instruction letter for the automatic sale of such 'sell-to-cover' shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Industry Context

Routine 'sell-to-cover' transactions are common across all industries, particularly in biotechnology companies like Avidity Biosciences, where executive compensation often includes equity awards such as RSUs. These transactions are standard practice for managing tax liabilities upon vesting.

Comparison to Industry Standards

• This type of "sell-to-cover" transaction is a standard practice for executives in publicly traded companies across various sectors, including biotech, to manage tax obligations arising from equity compensation.
• The use of a Rule 10b5-1 plan aligns with best practices for insider trading compliance, similar to executives at companies like Pfizer, Moderna, or Biogen, who also utilize such plans for pre-scheduled stock transactions.
• The reported price of $72.45 per share reflects the market value at the time of the pre-scheduled sale, which is consistent with how such transactions are executed across the industry.

Stakeholder Impact

• Minimal direct impact on shareholders, as this is a routine, non-discretionary transaction for tax purposes and not a signal of management's view on the company's prospects.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell-to-cover' transaction by a Chief Medical Officer to satisfy tax obligations related to RSU vesting. Such transactions are common and pre-planned under Rule 10b5-1, meaning they do not reflect a discretionary decision by the insider based on new material information. Therefore, this filing alone provides no new fundamental information to warrant a change in investment recommendation. An investor should 'hold' their position and look to other filings for material operational or financial updates.

Keywords

Avidity Biosciences, RNA, Steven George Hughes, Chief Medical Officer, Form 4, Insider Trading, Stock Sale, Sell-to-Cover, RSU Vesting, Tax Withholding, 10b5-1 Plan